In yesterday’s Wall Street session, Bristol-Myers Squibb Co. (NYSE:BMY) shares traded at $51.59, down -1.43% from the previous session.
BMY stock price is now 1.90% away from the 50-day moving average and -8.15% away from the 200-day moving average. The market capitalization of the company currently stands at $104.32B.
On February 06, 2024, Redburn Atlantic Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $77 to quote $54, while ‘BofA Securities’ rates the stock as ‘Neutral’
In other news, BOERNER CHRISTOPHER S., Chief Executive Officer bought 2,000 shares of the company’s stock on Dec 05 ’23. The stock was bought for $99,560 at an average price of $49.78. Upon completion of the transaction, the Chief Executive Officer now directly owns 82,672 shares in the company, valued at $4.27 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 28 ’23, Chief Executive Officer BOERNER CHRISTOPHER S. bought 3,071 shares of the business’s stock. A total of $150,049 was incurred on buying the stock at an average price of $48.86. This leaves the insider owning 79,384 shares of the company worth $4.1 million. A total of 0.08% of the company’s stock is owned by insiders.
During the past 12 months, Bristol-Myers Squibb Co. has had a low of $47.58 and a high of $71.07. As of last week, the company has a debt-to-equity ratio of 1.41, a current ratio of 1.43, and a quick ratio of 1.31. The fifty day moving average price for BMY is $50.62 and a two-hundred day moving average price translates $56.10 for the stock.
The latest earnings results from Bristol-Myers Squibb Co. (NYSE: BMY) was released for Dec, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.56, beating analysts’ expectations of $1.4 by 0.16. This compares to $0.95 EPS in the same period last year. The net profit margin was 17.83% and return on equity was 26.53% for BMY. The company reported revenue of $11.48 billion for the quarter, compared to $11.41 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.62 percent. For the current quarter, analysts expect BMY to generate $10.49B in revenue.
Bristol-Myers Squibb Co.(BMY) Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
